Lowest Price Guaranteed From USD 2,349
Published
October 2016
Pages
233
View Count
1832
The discovery of the second messengers, cAMP and cGMP, in 1958 led to a deeper understanding of the signal transduction processes behind physiological stimulation and response. Later, the identification of phosphodiesterases (PDEs) and the establishment of their role in diseases led to the development of drugs targeting this class of enzymes. PDEs are a complex superfamily of metallophosphohydrolase enzymes that regulate the activity of second messengers. The superfamily consists of 11 different gene families, ranging from PDE1 to PDE11. These enzymes can be differentiated, in terms of their 3D-structure, modes of regulation, cellular localization and sensitivity to inhibitors.
Until 1998, only non-selective PDE inhibitors were available in the market and were primarily indicated for providing symptomatic relief for respiratory diseases, including COPD and asthma. Post the launch of Viagra in 1998, several selective PDE inhibitors came into the market. At present, there are 13 PDE inhibitors commercially available in different geographies. Due to the involvement of PDEs in multiple cellular processes, inhibitors against these molecular targets are applicable across a diverse range of disease indications. It is worth mentioning that the introduction of PDE inhibitors brought a radical change in the treatment of erectile dysfunction. Consequently, these molecules now occupy a major share in the erectile dysfunction market. In addition, PDE inhibitors are also being developed to address the current unmet need for pharmacological interventions for the treatment of patients suffering from certain neurological diseases, cardiovascular diseases, respiratory diseases and dermatological diseases. Drug candidates targeting schizophrenia, atopic dermatitis, Huntington’s disease, COPD, asthma and Alzheimer’s disease are all in various phases of clinical development.
The success of the marketed PDE inhibitors has prompted several industry players to undertake initiatives in this area. The fragmented nature of the market is expected to increase the pace of innovation; as more molecules advance to late stage development and eventually get commercialized, we expect the new entrants to actively monetize this growing opportunity.
Scope of the Report
The "PDE Inhibitors Market, 2016-2026" study offers a comprehensive analysis of the current landscape of these therapies and an informed opinion on how the field is likely to evolve over the next decade. The market has gained traction during the last few years with many drug candidates designed to address a wide range of diseases. PDE5, with two blockbuster drugs (Viagra® and Cialis®), is one of the most researched PDE inhibitor subtype. In the recent past, another PDE inhibitor subtype, PDE4, has surfaced to address the unmet needs associated with respiratory diseases and dermatological disorders.
Among other things, the report provides the following information:
One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters such as target consumer segments, likely adoption rates and expected pricing, we have provided an estimate of the size of the market in the short-mid-term and long term. The base year for the report is 2016. To account for the uncertainties associated with the development of novel therapeutic classes and to add robustness to our model, we have provided three forecast scenarios portraying the conservative, base and optimistic tracks of the market’s evolution.
The opinions and insights presented in the report were influenced by discussions with experts in the industry. All figures and technical details presented in the report have been sourced and analyzed from publicly available data. All financial figures mentioned in this report are in USD, unless specified otherwise.
Chapter 2 provides an executive summary of the report. It offers a high level view on the evolution of PDE inhibitors market in the mid to long term.
Chapter 3 provides an introduction to PDE enzyme superfamily, including details on the historical timeline of this class of therapeutics and information on different PDE isozymes. The chapter highlights the structure of these enzymes and their role in different cellular activities. It also contains comprehensive information about selective and non-selective PDE inhibitors. In addition, the chapter provides details on the design of PDE inhibitors as well as importance of substrate specificity and potency.
Chapter 4 includes information on over 50 molecules that are either approved or are being evaluated in different stages of development (clinical / preclinical). It features a detailed and comprehensive analysis of the pipeline molecules highlighting the key therapeutic indications, PDE subtypes, phases of development, routes of administration and leading players in the field of PDE inhibitors.
Chapter 5 contains information on various genitourinary and cardiovascular diseases targeted by different PDE inhibitors. In addition to other elements, we have provided details on disease epidemiology and information on specific PDE inhibitors that are involved in the treatment of a particular indication. The chapter also provides comprehensive profiles of drug candidates in development (phase II or higher) for the treatment of genitourinary and cardiovascular diseases. Each profile presents an overview of the drug developer, portfolio of PDE inhibitors, details on clinical trials, current status of development and key clinical results. In addition, the chapter highlights the emerging trends on social media related to PDE inhibitors. It presents an overview of the popularity of the keywords phosphodiesterase inhibitor and PDE inhibitor on Twitter over the last five years.
Chapter 6 contains information on various neurological diseases being targeted by different PDE inhibitors. In addition to other elements, we have provided details on disease epidemiology and information on specific PDE inhibitors that are involved in the treatment of a particular indication. The chapter also provides comprehensive profiles of drug candidates in development (phase II or higher) for the treatment of neurological diseases. Each profile presents an overview of the drug developer, portfolio of PDE inhibitors, details on clinical trials, current status of development and key clinical results.
Chapter 7 contains information on various dermatological diseases being targeted by different PDE inhibitors. In addition to other elements, we have covered details on disease epidemiology and information on specific PDE inhibitors that are involved in the treatment of a particular indication. The chapter also provides detailed profiles of the molecules in development (phase II or higher) for the treatment of dermatological diseases. Each profile presents an overview of the drug developer, portfolio of PDE inhibitors, details on clinical trials, current status of development and key clinical results.
Chapter 8 contains information on various respiratory diseases and other key indications targeted by different PDE inhibitors. In addition to other elements, we have covered details on disease epidemiology and information on specific PDE inhibitors that are involved in the treatment of a particular indication. The chapter also provides detailed profiles of the molecules in development (phase II or higher) for the treatment of respiratory diseases and other key indications. Each profile presents an overview of the drug developer, portfolio of PDE inhibitors, details on clinical trials, current status of development and key clinical results.
Chapter 9 presents an analysis of the key opinion leaders (KOLs) in this domain. It contains schematic representations of world maps highlighting the geographical locations of these eminent scientists / researchers. The chapter presents a detailed 2X2 analysis to assess the relative experience of certain KOLs based on the number of clinical studies and the highest phase of development of a clinical trial investigated by them.
Chapter 10 presents a detailed market forecast of PDE inhibitors and a discussion on the overall financial opportunity in this domain. It includes future sales projections for 13 molecules in advanced stages of development. These estimates take into account the target patient population, the existing competition, likely adoption rate and the expected price of each therapy.
Chapter 11 focusses on the various side effects reported by patients treated using these drugs. In addition, the chapter lists the PDE inhibitors that have been terminated during development due to various reasons.
Chapter 12 provides a summary of the overall report. In this chapter, we present a list of key takeaways from the report and our independent opinion on the nature and potential of the PDE inhibitors market. The insights presented in this chapter are based on the research and analysis described in previous chapters.
Chapter 13 contains a collection of interview transcripts of discussions held with some of the key players in the industry.
Chapters 14 and 15 are appendices, which provide tabulated data and a list of companies mentioned in the report, respectively.
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Context and Background
3.2. Phosphodiesterases: A Brief History
3.3. Phosphodiesterases: An Overview
3.3.1. PDE Isozymes: Structure
3.3.2. PDE Isozymes: Function
3.4. PDE Inhibitors
3.4.1. Designing PDE Inhibitors
3.4.2. Substrate Specificity and Potency
4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. PDE Inhibitors: A Promising Pipeline
4.3. PDE Inhibitors: Pipeline Analysis
4.3.1. PDE Inhibitors: Distribution by Phase of Development
4.3.2. PDE Inhibitors: Distribution by PDE Subtypes
4.3.3. PDE Inhibitors: Distribution by Therapeutic Areas
4.3.4. PDE Inhibitors: Distribution by Route of Administration
4.3.5. PDE Inhibitors: Distribution by Geography
4.3.6. PDE Inhibitors: Leading Players
5. GENITOURINARY AND CARDIOVASCULAR DISEASES
5.1. Context and Background
5.2. Genitourinary Diseases
5.2.1. Erectile Dysfunction
5.2.1.1. Introduction and Epidemiology
5.2.1.2. Most Prominent PDE Inhibitor Subtypes
5.3.1. Pulmonary Hypertension
5.3.1.1. Introduction and Epidemiology
5.3.1.2. Most Prominent PDE Inhibitor Subtypes
5.4. PDE Inhibitors under Development for Genitourinary Diseases and Cardiovascular Diseases
5.5. Hanmi Pharmaceutical
5.5.1. Company Overview
5.5.2. Financial Performance
5.5.3. PDE Inhibitor Pipeline
5.5.3.1. HGP1207
5.5.3.1.1. Product Overview
5.5.3.1.2. Current Status of Development
5.5.3.1.3. Clinical Trials
5.5.3.2. HCP1303
5.5.3.2.1. Product Overview
5.5.3.2.2. Current Status of Development
5.5.3.2.3. Clinical Trials
5.6. PDE Inhibitors: Trends on Social Media
5.7. Trend on Twitter
5.7.1. Most Popular Marketed Drugs
5.7.2. Most Popular PDE Inhibitor Subtypes
5.7.2.1. Most Popular Keywords (Word Cloud Representation)
6. NEUROLOGICAL DISEASES
6.1. Chapter Overview
6.2. Schizophrenia
6.2.1. Introduction and Epidemiology
6.3. Huntington’s Disease
6.3.1. Introduction and Epidemiology
6.3.2. Most Prominent PDE Inhibitor Subtypes
6.4. Alzheimer’s Disease
6.4.1. Introduction and Epidemiology
6.4.2. Most Prominent PDE Inhibitor Subtypes
6.5. PDE Inhibitors under Development for Neurological Diseases
6.6. Boehringer Ingelheim
6.6.1. Company Overview
6.6.2. Financial Performance
6.6.3. PDE Inhibitor Pipeline
6.6.3.1. BI 409306
6.6.3.1.1. Product Overview
6.6.3.1.2. Current Status of Development
6.6.3.1.3. Clinical Trials
6.6.3.1.4. Key Clinical Trial Results
6.7. Takeda Pharmaceuticals
6.7.1. Company Overview
6.7.2. Financial Performance
6.7.3. PDE Inhibitor Pipeline
6.7.3.1. TAK-063
6.7.3.1.1. Product Overview
6.7.3.1.2. Current Status of Development
6.7.3.1.3. Clinical Trials
6.7.3.1.4. Key Clinical Trial Results
6.8. Pfizer
6.8.1. Company Overview
6.8.2. Financial Performance
6.8.3. PDE Inhibitor Pipeline
6.8.3.1. PF-02545920
6.8.3.1.1. Product Overview
6.8.3.1.2. Current Status of Development
6.8.3.1.3. Clinical Trials
6.8.3.1.4. Key clinical Trial Results
6.8.4. Collaborations
6.9. Dart NeuroScience
6.9.1. Company Overview
6.9.2. PDE Inhibitor Pipeline
6.9.2.1. HT-0712 / IPL-455903
6.9.2.1.1. Product Overview
6.9.2.1.2. Current Status of Development
6.9.2.1.3. Clinical Trials
6.9.2.1.4. Key Clinical Trial Results
6.10. Omeros Corporation
6.10.1. Company Overview
6.10.2. Financial Performance
6.10.3. PDE Inhibitor Pipeline
6.10.3.1. OMS824
6.10.3.1.1. Product Overview
6.10.3.1.2. Current Status of Development
6.10.3.1.3. Clinical Trials
6.10.3.1.4. Key Clinical Trial Results
6.10.4. Collaborations
7. DERMATOLOGICAL DISORDERS
7.1. Chapter Overview
7.2. Atopic Dermatitis
7.2.1. Introduction and Epidemiology
7.2.2. Most Prominent PDE Inhibitor Subtypes
7.3. Psoriasis
7.3.1. Introduction and Epidemiology
7.3.2. Most Prominent PDE Inhibitor Subtypes
7.4. PDE Inhibitors under Development For Dermatology
7.5. Anacor Pharmaceuticals (a part of Pfizer)
7.5.1. Company Overview
7.5.2. Financial Performance
7.5.3. PDE Inhibitor Pipeline
7.5.3.1. Crisaborole / AN2728
7.5.3.1.1. Product Overview
7.5.3.1.2. Current Status of Development
7.5.3.1.3. Clinical Trials
7.5.3.1.4. Key Clinical Trials
7.6. Otsuka
7.6.1. Company Overview
7.6.2. Financial Performance
7.6.3. PDE Inhibitor Pipeline
7.6.3.1. OPA-15406 / MM36
7.6.3.1.1. Product Overview
7.6.3.1.2. Current Status of Development
7.6.3.1.3. Clinical Trials
7.6.3.1.4. Key Clinical Trial Results
7.6.4. Collaborations
7.7. Roivant Sciences
7.7.1. Company Overview
7.7.2. PDE Inhibitor Pipeline
7.7.2.1. RVT-501
7.7.2.1.1. Product Overview
7.7.2.1.2. Current Status of Development
7.7.2.1.3. Clinical Trials
7.7.2.1.4. Key Clinical Trial Results
7.7.3. Collaborations
8. RESPIRATORY DISEASES AND OTHER INDICATIONS
8.1. Chapter Overview
8.2. Respiratory Diseases
8.2.1. COPD
8.2.1.1. Introduction and Epidemiology
8.2.1.2. Most Prominent PDE Inhibitor Subtypes
8.2.2. Asthma
8.2.2.1. Introduction and Epidemiology
8.2.2.2. Most Prominent PDE Inhibitor Subtypes
8.2.3. PDE Inhibitors under Development for Respiratory Diseases
8.3. Other Indications
8.3.1. NAFLD / NASH
8.3.1.1. Introduction and Epidemiology
8.3.1.2. Most Prominent PDE Inhibitor Subtypes
8.3.2. PDE Inhibitors under Development for Other Indications
8.4. Chiesi Farmaceutici
8.4.1. Company Overview
8.4.2. Financial Performance
8.4.3. PDE Inhibitor Pipeline
8.4.3.1. CHF6001
8.4.3.1.1. Product Overview
8.4.3.1.2. Current Status of Development
8.4.3.1.3. Clinical Trials
8.4.3.1.4. Key Clinical Trial Results
8.5. Verona Pharma
8.5.1. Company Overview
8.5.2. Financial Performance
8.5.3. PDE Inhibitor Pipeline
8.5.3.1. RPL554
8.5.3.1.1. Product Overview
8.5.3.1.2. Current Status of Development
8.5.3.1.3. Clinical Trials
8.5.3.1.4. Key Clinical Trial Results
8.5.4. Collaborations
8.6. NuSirt Biopharma
8.6.1. Company Overview
8.6.2. Financial Performance
8.6.3. PDE Inhibitor Pipeline
8.6.3.1. NS-0200
8.6.3.1.1. Product Overview
8.6.3.1.2. Current Status of Development
8.6.3.1.3. Clinical Trials
8.6.3.1.4. Key Clinical Trial Results
9. KOL ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.2.1. PDE Inhibitors: Prominent Researchers
9.2.2. PDE Inhibitors: Leading Key Opinion Leaders
10. MARKET OPPORTUNITY
10.1. Chapter Overview
10.2. Scope and Limitations
10.3. Research Methodology
10.4. Overall PDE Inhibitors Market, 2016-2026
10.4.1. Overall PDE Inhibitors Market: Distribution by Therapeutic Area
10.4.2. Overall PDE Inhibitors Market: Distribution by PDE Subtype
10.5. Daliresp (AstraZeneca)
10.5.1. Target Patient Population
10.5.2. Sales Forecast
10.6. OTEZLA (Celgene)
10.6.1. Target Patient Population
10.6.2. Sales Forecast
10.7. Crisaborole (Anacor Pharmaceuticals)
10.7.1. Target Patient Population
10.7.2. Sales Forecast
10.8. OPA-15406 / MM36 (Otsuka Pharmaceutical / Medimetriks Pharmaceuticals)
10.8.1. Target Patient Population
10.8.2. Sales Forecast
10.9. HT-0712 (Dart NeuroScience)
10.9.1. Target Patient Population
10.9.2. Sales Forecast
10.10. RPL554 (Verona Pharma)
10.10.1. Target Patient Population
10.10.2. Sales Forecast
10.11. BI409306 (Boehringer Ingelheim)
10.11.1. Target Patient Population
10.11.2. Sales Forecast
10.12. NS-0200 (NuSirt Biopharma)
10.12.1. Target Patient Population
10.12.2. Sales Forecast
10.13. RVT-501 (Roivant Sciences)
10.13.1. Target Patient Population
10.13.2. Sales Forecast
10.14. CHF6001 (Chiesi Farmaceutici)
10.14.1. Target Patient Population
10.14.2. Sales Forecast
10.15. PF-02545920 (Pfizer)
10.15.1. Target Patient Population
10.15.2. Sales Forecast
10.16. TAK-063 (Takeda Pharmaceutical)
10.16.1. Target Patient Population
10.16.2. Sales Forecast
10.17. OMS824 (Omeros Corporation)
10.17.1. Target Patient Population
10.17.2. Sales Forecast
11. DISCONTINUED MOLECULES AND SIDE EFFECTS
11.1. Chapter Overview
11.2. Discontinued Molecules
11.2.1. Discontinued / Terminated Molecules: Distribution by Phase of Development
11.2.2. Discontinued / Terminated Molecules: Distribution by PDE Subtype
11.3. Precautionary Notes and Common Side Effects
11.3.1. PDE5 Inhibitors
11.3.2. PDE4 Inhibitors
12 CONCLUSION
12.1. The Pipeline Is Dominated By the Presence of PDE4, PDE5 and PDE10 Inhibitors
12.2. Both Big and Small Pharma Players, Keen to Leverage the Broad Spectrum Applicability of This Drug Class, are Actively Involved
12.3. Involvement of Several Prominent Researchers in This Domain and Growing Social Media Chatter Are Indicative of the Popularity of This Drug Class
12.4. Varying Opportunity across Disease Indications is Likely to Translate into a Lucrative Future Growth Potential
13. INTERVIEW TRANSCRIPTS
14. APPENDIX: TABULATED DATA
15. APPENDIX: LIST OF COMPANIES AND RESEARCH ORGANIZATIONS
Figure 3.1 Schematic Representation of Phosphodiesterases
Figure 3.2 PDE Isozymes: Function
Figure 4.1 PDE Inhibitors: Distribution by Phase of Development (Marketed/ Phase III / Phase II / Phase I / Preclinical / Discovery)
Figure 4.2 PDE Inhibitors: Distribution by PDE Subtypes
Figure 4.3 PDE Inhibitors: Distribution by PDE Subtypes and Phase of Development
Figure 4.4 PDE Inhibitors: Distribution by Therapeutic Areas
Figure 4.5 PDE Inhibitors: Distribution by Key Therapeutic Indications
Figure 4.6 PDE Inhibitors: Distribution by PDE Subtype, Therapeutic Area and Phase of Development
Figure 4.7 PDE Inhibitors: Distribution by Route of Administration
Figure 4.8 PDE Inhibitors: Distribution by Geography
Figure 4.9 PDE Inhibitors: Regional Landscape
Figure 4.10 PDE Inhibitors: Leading Players
Figure 5.1 Hanmi Science Holding: Annual Revenues, 2011 - H1 2016 (KRW Billion)
Figure 5.2 PDE Inhibitors: Most Popular Marketed Drugs on Twitter, 2010-2015
Figure 5.3 PDE Inhibitors: Most Popular PDE Inhibitor Subtypes on Twitter, 2010-2015
Figure 5.4 PDE Inhibitors: Most Popular Keywords on Twitter, 2010-2015
Figure 6.1 Boehringer Ingelheim: Annual Revenues, 2010-2015 (EUR Billion)
Figure 6.2 Boehringer Ingelheim: Revenues Distribution by Business Segments, 2015 (EUR Billion)
Figure 6.3 Takeda Pharmaceuticals: Annual Revenues, 2010-Q1 2016 (JPY Billion)
Figure 6.4 Takeda Pharmaceuticals: Revenue Distribution by Business Segments, 2015 (JPY Billion)
Figure 6.5 Pfizer: Annual Revenues, 2011 – H1 2016 (USD Billion)
Figure 6.6 Pfizer: Revenue Distribution by Business Segments, 2015 (USD Billion)
Figure 6.7 Omeros Corporation: Annual Revenues, 2011- H1 2016 (USD Million)
Figure 6.8 Omeros Corporation: Funding Instances (USD Million)
Figure 7.1 Anacor Pharmaceuticals: Annual Revenues, 2011 – Q1 2016 (USD Million)
Figure 7.2 Otsuka: Annual Revenues, 2011-H1 2016 (JPY Billion)
Figure 7.3 Otsuka: Revenue Distribution by Business Segments, 2015 (JPY Billion)
Figure 8.1 Chiesi Farmaceutici: Annual Revenues, 2010-2015 (EUR Billion)
Figure 8.2 Verona Pharma: Funding Instances (GBP Million)
Figure 8.3 NuSirt Biopharma: Funding Instances (USD Million)
Figure 9.1 PDE Inhibitors: Mapping Prominent Researchers
Figure 9.2 PDE Inhibitors: Leading Key Opinion Leaders
Figure 10.1 Overall PDE Inhibitors Market, 2016-2026, Base Scenario (USD Million)
Figure 10.2 Overall PDE Inhibitors Market: Distribution by Therapeutic Area, 2016-2026 (USD Million)
Figure 10.3 Evolution of PDE Inhibitors Market: Distribution by Therapeutic Area 2016, 2021, 2026 (Base Scenario)
Figure 10.4 Overall PDE Inhibitors Market: Distribution by PDE Subtype, 2016-2026 (USD Million)
Figure 10.5 Evolution of PDE Inhibitors Market: Distribution by PDE Subtype 2016, 2021, 2026 (Base Scenario)
Figure 10.6 Daliresp Sales Forecast, Base Scenario (USD Million)
Figure 10.7 OTEZLA Sales Forecast, Base Scenario (USD Million)
Figure 10.8 Crisaborole Sales Forecast, Base Scenario (USD Million)
Figure 10.9 OPA-15406 Sales Forecast, Base Scenario (USD Million)
Figure 10.10 HT-0712 Sales Forecast, Base Scenario (USD Million)
Figure 10.11 RPL554 Sales Forecast, Base Scenario (USD Million)
Figure 10.12 BI409306 Sales Forecast, Base Scenario (USD Million)
Figure 10.13 NS-0200 Sales Forecast, Base Scenario (USD Million)
Figure 10.14 RVT-501 Sales Forecast, Base Scenario (USD Million)
Figure 10.15 CHF6001 Sales Forecast, Base Scenario (USD Million)
Figure 10.16 PF-02545920 Sales Forecast, Base Scenario (USD Million)
Figure 10.17 TAK-063 Sales Forecast, Base Scenario (USD Million)
Figure 10.18 OMS824 Sales Forecast, Base Scenario (USD Million)
Figure 11.1 Discontinued / Terminated Molecules: Distribution by Phase of Termination
Figure 11.2 Discontinued / Terminated Molecules: Distribution by PDE Subtype
Figure 12.1 PDE Inhibitors: Developer Landscape
Figure 12.2 PDE Inhibitors: Key Indications
Figure 12.3 PDE Inhibitors: Market Opportunity across Different Disease Indications
Figure 12.4 PDE Inhibitors Market: Conservative, Base and Optimistic Forecast Scenarios, 2016-2026 (USD Billion)
Table 3.1 PDE Superfamily
Table 3.2 Non-selective PDE Inhibitors
Table 4.1 PDE Inhibitors: Marketed and Developmental Pipeline
Table 4.2 PDE Inhibitors: Unknown Status
Table 5.1 PDE Inhibitors: Genitourinary and Cardiovascular Diseases
Table 5.2 Hanmi Pharmaceuticals: PDE Inhibitor Pipeline
Table 5.3 HGP1207: Current Status of Development
Table 5.4 HGP1207: Clinical Trials
Table 5.5 HCP1303: Current Status of Development
Table 5.6 HCP1303: Clinical Trials
Table 6.1 PDE Inhibitors Pipeline: Neurological Diseases
Table 6.2 Boehringer Ingelheim: PDE Inhibitor Pipeline
Table 6.3 BI 409306: Current Status of Development
Table 6.4 BI 409306: Clinical Trials
Table 6.5 BI 409306: Clinical Trial Results (NCT01505894)
Table 6.6 BI 409306: Clinical Trial Results (NCT01611311)
Table 6.7 Takeda Pharmaceuticals: PDE Inhibitor Pipeline
Table 6.8 TAK-063: Current Status of Development
Table 6.9 TAK-063: Clinical Trials
Table 6.10 Pfizer: PDE Inhibitor Pipeline
Table 6.11 PF-02545920: Current Status of Development
Table 6.12 PF-02545920: Clinical Trials
Table 6.13 Dart NeuroScience: PDE Inhibitor Pipeline
Table 6.14 HT-0712: Current Status of Development
Table 6.15 HT-0712: Clinical Trials
Table 6.16 Omeros Corporation: PDE Inhibitor Pipeline
Table 6.17 OMS824: Current Status of Development
Table 6.18 OMS824: Clinical Trials
Table 7.1 PDE Inhibitors Pipeline: Dermatological Disorders
Table 7.2 Anacor Pharmaceuticals: PDE Inhibitors Pipeline
Table 7.3 Crisaborole: Current Status of Development
Table 7.4 Crisaborole: Clinical Trials
Table 7.5 Crisaborole: Phase III Clinical Trial Results
Table 7.6 Otsuka: PDE Inhibitor Pipeline
Table 7.7 OPA-15406: Current Status of Development
Table 7.8 OPA-15406: Clinical Trials
Table 7.9 Roivant Sciences: PDE Inhibitor Pipeline
Table 7.10 RVT-501: Current Status of Development
Table 7.11 RVT-501: Clinical Trials
Table 8.1 PDE Inhibitors Pipeline: Respiratory Diseases
Table 8.2 PDE Inhibitors: Marketed and Pipeline (Other Indications)
Table 8.3 Chiesi Farmaceutici: PDE Inhibitor Pipeline
Table 8.4 CHF6001: Current Status of Development
Table 8.5 CHF6001: Clinical Trials
Table 8.6 Verona Pharma: PDE Inhibitor Pipeline
Table 8.7 RLP554: Current Status of Development
Table 8.8 RLP554: Clinical Trials
Table 8.9 NuSirt: PDE Inhibitor Pipeline
Table 8.10 NS-0200: Current Status of Development
Table 8.11 NS-0200: Clinical Trials
Table 9.1 KOLs: Phase IV Clinical Trials
Table 9.2 KOLs: Phase III Clinical Trials
Table 9.3 KOLs: Phase II Clinical Trials
Table 9.4 KOLs: Phase I Clinical Trials
Table 9.5 KOLs: Other Clinical Trials
Table 10.1 Marketed / Late Phase PDE Inhibitors: Actual / Estimated Launch Year
Table 10.2 Daliresp: Target Patient Population
Table 10.3 OTEZLA: Target Patient Population
Table 10.4 Crisaborole: Target Patient Population
Table 10.5 OPA-15406: Target Patient Population
Table 10.6 HT-0712: Target Patient Population
Table 10.7 RPL554: Target Patient Population
Table 10.8 BI409306: Target Patient Population
Table 10.9 NS-0200: Target Patient Population
Table 10.10 RVT-501: Target Patient Population
Table 10.11 CHF6001: Target Patient Population
Table 10.12 PF-02545920: Target Patient Population
Table 10.13 TAK-063: Target Patient Population
Table 10.14 OMS824: Target Patient Population
Table 11.1 PDE Inhibitors: Discontinued / Terminated Molecules,
Table 14.1 PDE Inhibitors: Distribution by Phase of Development (Marketed/ Phase III / Phase II / Phase I / Preclinical / Discovery)
Table 14.2 PDE Inhibitors: Distribution by PDE Subtypes
Table 14.3 PDE Inhibitors: Distribution by PDE Subtypes and Phase of Development
Table 14.4 PDE Inhibitors: Distribution by Therapeutic Areas
Table 14.5 PDE Inhibitors: Distribution by Key Therapeutic Indications
Table 14.6 PDE Inhibitors: Distribution by Route of Administration
Table 14.7 PDE Inhibitors: Distribution by Geography
Table 14.8 PDE Inhibitors: Leading Players
Table 14.9 Hanmi Science Holding: Annual Revenues, 2011 - H1 2016 (KRW Billion)
Table 14.10 Boehringer Ingelheim: Annual Revenues, 2010-2015 (EUR Billion)
Table 14.11 Boehringer Ingelheim: Revenues Distribution by Business Segments, 2015 (EUR Billion)
Table 14.12 Takeda Pharmaceuticals: Annual Revenues, 2010-Q1 2016 (JPY Billion)
Table 14.13 Takeda Pharmaceuticals: Revenue Distribution by Business Segments, 2015 (JPY Billion)
Table 14.14 Pfizer: Annual Revenues, 2011 – Q1 2016 (USD Billion)
Table 14.15 Pfizer: Revenue Distribution by Business Segments, 2015 (USD Billion)
Table 14.16 Omeros Corporation: Annual Revenue, 2011- H1 2016 (USD Million)
Table 14.17 Omeros Corporation: Funding Instances (USD Million)
Table 14.18 Anacor Pharmaceuticals: Annual Revenues, 2011 – Q1 2016 (USD Million)
Table 14.19 Otsuka: Annual Revenues, 2011-H1 2016 (JPY Billion)
Table 14.20 Otsuka: Revenue Distribution by Business Segments, 2015 (JPY Billion)
Table 14.21 Chiesi Farmaceutici: Annual Revenue, 2010-2015 (EUR Billion)
Table 14.22 Verona Pharma: Funding Instances (GBP Million)
Table 14.23 NuSirt Biopharma: Funding Instances (USD Million)
Table 14.24 Overall PDE Inhibitors Market, 2016-2026, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)
Table 14.25 Overall PDE Inhibitors Market: Distribution by Therapeutic Area, 2016-2026 (USD Million)
Table 14.26 Overall PDE Inhibitors Market: Distribution by PDE Subtype, 2016-2026 (USD Million)
Table 14.27 Daliresp Sales Forecast, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)
Table 14.28 OTEZLA Sales Forecast, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)
Table 14.29 Crisaborole Sales Forecast, Base Scenario (USD Million)
Table 14.30 OPA-15406 Sales Forecast, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)
Table 14.31 HT-0712 Sales Forecast, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)
Table 14.32 RPL554 Sales Forecast, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)
Table 14.33 BI409306 Sales Forecast, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)
Table 14.34 NS-0200 Sales Forecast, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)
Table 14.35 RVT-501 Sales Forecast, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)
Table 14.36 CHF6001 Sales Forecast, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)
Table 14.37 PF-02545920 Sales Forecast, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)
Table 14.38 TAK-063 Sales Forecast, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)
Table 14.39 OMS824 Sales Forecast, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)
Table 14.40 Discontinued / Terminated Molecules: Distribution by Phase of Termination
Table 14.41 Discontinued / Terminated Molecules: Distribution by PDE Subtype
The following companies and organizations have been mentioned in the study.
Discounts available for multiple report purchases
sales@rootsanalysis.com